Cargando…
Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study
BACKGROUND: Patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) who receive systemic chemotherapy have a poor prognosis. This study aimed to determine if one-shot cisplatin (CDDP) chemotherapy via hepatic arterial infusion (HAI) combined with radiation therapy (RT) prior to...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161561/ https://www.ncbi.nlm.nih.gov/pubmed/35655156 http://dx.doi.org/10.1186/s12876-022-02359-x |
_version_ | 1784719511410180096 |
---|---|
author | Naruto, Kensuke Kawaoka, Tomokazu Kodama, Kenichiro Ogawa, Yutaro Amioka, Kei Yoshikawa, Yuki Kikukawa, Chihiro Suehiro, Yousuke Yamaoka, Kenji Ando, Yuwa Kosaka, Yumi Uchikawa, Shinsuke Nakahara, Takashi Murakami, Eisuke Ono, Atsushi Uchida, Takuro Yamauchi, Masami Okamoto, Wataru Takahashi, Shoichi Imamura, Michio Chosa, Keigo Awai, Kazuo Kubo, Katsumaro Nagata, Yasushi Chayama, Kazuaki Aikata, Hiroshi |
author_facet | Naruto, Kensuke Kawaoka, Tomokazu Kodama, Kenichiro Ogawa, Yutaro Amioka, Kei Yoshikawa, Yuki Kikukawa, Chihiro Suehiro, Yousuke Yamaoka, Kenji Ando, Yuwa Kosaka, Yumi Uchikawa, Shinsuke Nakahara, Takashi Murakami, Eisuke Ono, Atsushi Uchida, Takuro Yamauchi, Masami Okamoto, Wataru Takahashi, Shoichi Imamura, Michio Chosa, Keigo Awai, Kazuo Kubo, Katsumaro Nagata, Yasushi Chayama, Kazuaki Aikata, Hiroshi |
author_sort | Naruto, Kensuke |
collection | PubMed |
description | BACKGROUND: Patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) who receive systemic chemotherapy have a poor prognosis. This study aimed to determine if one-shot cisplatin (CDDP) chemotherapy via hepatic arterial infusion (HAI) combined with radiation therapy (RT) prior to systemic chemotherapy could improve the outcomes of these patients. METHODS: This study consisted of 32 HCC patients with the following eligibility criteria: (i) portal vein invasion 3/4 and/or hepatic vein invasion 2/3; (ii) received one-shot CDDP via HAI; (iii) received RT for MVI, (iv) a Child–Pugh score ≤ 7; and (v) an Eastern Clinical Oncology Group Performance Status score of 0 or 1. To determine the therapeutic effect, we collected information on patient characteristics and took contrast-enhanced computed tomography at the start of the therapy and every 2 to 4 months after the start of therapy. We evaluated the overall response of the tumor and tumor thrombosis according to modified Response Evaluation Criteria in Solid Tumors. We assessed patient data using the Mann–Whitney U and Fisher exact tests and evaluated overall survival and progression-free survival using the log-rank test. RESULTS: The overall response rate at the first evaluation performed a median of 1.4 weeks after HAI was 16% for the main intrahepatic tumor and 59% for the MVI. The best responses were the same as those of the first-time responses. The duration of median survival was 8.6 months, and progression-free survival of the main intrahepatic tumor was 3.2 months. Predictive factors for overall survival were the relative tumor volume in the liver and the first therapeutic response of MVI. There were no severe adverse events or radiation-induced hepatic complications. CONCLUSIONS: One-shot CDDP via HAI and RT were well tolerated and showed immediate and favorable control of MVI. Thus, this combination shows potential as a bridging therapy to systemic chemotherapy. |
format | Online Article Text |
id | pubmed-9161561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91615612022-06-03 Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study Naruto, Kensuke Kawaoka, Tomokazu Kodama, Kenichiro Ogawa, Yutaro Amioka, Kei Yoshikawa, Yuki Kikukawa, Chihiro Suehiro, Yousuke Yamaoka, Kenji Ando, Yuwa Kosaka, Yumi Uchikawa, Shinsuke Nakahara, Takashi Murakami, Eisuke Ono, Atsushi Uchida, Takuro Yamauchi, Masami Okamoto, Wataru Takahashi, Shoichi Imamura, Michio Chosa, Keigo Awai, Kazuo Kubo, Katsumaro Nagata, Yasushi Chayama, Kazuaki Aikata, Hiroshi BMC Gastroenterol Research BACKGROUND: Patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) who receive systemic chemotherapy have a poor prognosis. This study aimed to determine if one-shot cisplatin (CDDP) chemotherapy via hepatic arterial infusion (HAI) combined with radiation therapy (RT) prior to systemic chemotherapy could improve the outcomes of these patients. METHODS: This study consisted of 32 HCC patients with the following eligibility criteria: (i) portal vein invasion 3/4 and/or hepatic vein invasion 2/3; (ii) received one-shot CDDP via HAI; (iii) received RT for MVI, (iv) a Child–Pugh score ≤ 7; and (v) an Eastern Clinical Oncology Group Performance Status score of 0 or 1. To determine the therapeutic effect, we collected information on patient characteristics and took contrast-enhanced computed tomography at the start of the therapy and every 2 to 4 months after the start of therapy. We evaluated the overall response of the tumor and tumor thrombosis according to modified Response Evaluation Criteria in Solid Tumors. We assessed patient data using the Mann–Whitney U and Fisher exact tests and evaluated overall survival and progression-free survival using the log-rank test. RESULTS: The overall response rate at the first evaluation performed a median of 1.4 weeks after HAI was 16% for the main intrahepatic tumor and 59% for the MVI. The best responses were the same as those of the first-time responses. The duration of median survival was 8.6 months, and progression-free survival of the main intrahepatic tumor was 3.2 months. Predictive factors for overall survival were the relative tumor volume in the liver and the first therapeutic response of MVI. There were no severe adverse events or radiation-induced hepatic complications. CONCLUSIONS: One-shot CDDP via HAI and RT were well tolerated and showed immediate and favorable control of MVI. Thus, this combination shows potential as a bridging therapy to systemic chemotherapy. BioMed Central 2022-06-02 /pmc/articles/PMC9161561/ /pubmed/35655156 http://dx.doi.org/10.1186/s12876-022-02359-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Naruto, Kensuke Kawaoka, Tomokazu Kodama, Kenichiro Ogawa, Yutaro Amioka, Kei Yoshikawa, Yuki Kikukawa, Chihiro Suehiro, Yousuke Yamaoka, Kenji Ando, Yuwa Kosaka, Yumi Uchikawa, Shinsuke Nakahara, Takashi Murakami, Eisuke Ono, Atsushi Uchida, Takuro Yamauchi, Masami Okamoto, Wataru Takahashi, Shoichi Imamura, Michio Chosa, Keigo Awai, Kazuo Kubo, Katsumaro Nagata, Yasushi Chayama, Kazuaki Aikata, Hiroshi Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study |
title | Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study |
title_full | Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study |
title_fullStr | Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study |
title_full_unstemmed | Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study |
title_short | Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study |
title_sort | efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161561/ https://www.ncbi.nlm.nih.gov/pubmed/35655156 http://dx.doi.org/10.1186/s12876-022-02359-x |
work_keys_str_mv | AT narutokensuke efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT kawaokatomokazu efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT kodamakenichiro efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT ogawayutaro efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT amiokakei efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT yoshikawayuki efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT kikukawachihiro efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT suehiroyousuke efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT yamaokakenji efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT andoyuwa efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT kosakayumi efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT uchikawashinsuke efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT nakaharatakashi efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT murakamieisuke efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT onoatsushi efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT uchidatakuro efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT yamauchimasami efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT okamotowataru efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT takahashishoichi efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT imamuramichio efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT chosakeigo efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT awaikazuo efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT kubokatsumaro efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT nagatayasushi efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT chayamakazuaki efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy AT aikatahiroshi efficacyandsafetyofchemoradiationtherapyusingoneshotcisplatinviahepaticarterialinfusionforadvancedhepatocellularcarcinomawithmajormacrovascularinvasionasinglearmretrospectivecohortstudy |